Hormonal
Semaglutide 0.4 mg does not significantly improve liver fibrosis stage compared to placebo in patients with NASH and fibrosis stage F2 or F3.
For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks does not significantly improve liver fibrosis stage compared to placebo, despite improving NASH resolution. This suggests that while semaglutide is effective for resolving NASH, it may not be sufficient for reversing fibrosis in all patients.
An improvement in fibrosis stage occurred in 43% of the patients in the 0.4-mg group and in 33% of the patients in the placebo group (P = 0.48).
Why this rating
Phase 2, randomized, double-blind, placebo-controlled trial with 320 patients.
Source
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al. · New England Journal of Medicine · 2020
DOI 10.1056/nejmoa2028395
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →